2295-58-1
2295-58-1 结构式
基本信息
三羟苯丙酮
1-(2,4,6-三羟基苯基)丙-1-酮
2,4,6-TRIHYDROXYPROPIOPHENONE
FLOPROPIONE
PHLOPROPIOPHENONE
PHLOROPROPIOPHENONE
1-(2,4,6-trihydroxyphenyl)-1-propanon
1-(2,4,6-Trihydroxyphenyl)-1-propanone
13907 R. P.
13907r.p.
1-Propanone, 1-(2,4,6-trihydroxyphenyl)-
2’,4’,6’-trihydroxy-propiophenon
Argobyl
Chlonarin
Cospanon
Ecapron
Flopion
Flopropion
Gallepronin
Gasstenon
Labroda
物理化学性质
制备方法
108-73-6
79-03-8
2295-58-1
通用程序：将无水AlCl3（4当量）缓慢加入至搅拌的间苯三酚（1当量）于CS2的悬浮液中。随后，在30分钟内逐滴加入硝基苯。将反应混合物于55℃下回流30分钟。接着，在30分钟内缓慢加入溶解于硝基苯中的丙酰氯（1当量），并继续加热反应混合物30分钟。反应完成后，在搅拌下使混合物冷却至室温，随后缓慢倒入冰水浴中。加入3M HCl以淬灭反应。通过减压蒸馏除去有机溶剂，所得油状残余物用Et2O萃取。萃取后，蒸发去除Et2O，粗产物通过快速色谱法（洗脱剂：石油醚（沸点50-70℃）/乙酸乙酯，比例从5:1渐变至3:1）进行纯化。
参考文献：
[1] Agricultural and Biological Chemistry, 1985, vol. 49, # 3, p. 719 - 724
[2] European Journal of Medicinal Chemistry, 2014, vol. 85, p. 621 - 628
[3] Australian Journal of Chemistry, 2005, vol. 58, # 7, p. 551 - 555
[4] European Journal of Medicinal Chemistry, 2018, vol. 155, p. 255 - 262
[5] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 13, p. 4402 - 4409
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/09/19 | S4249 | 夫洛丙酮 Flopropione | 2295-58-1 | 50mg | 800.41元 |
| 2025/05/22 | T0887 | 2',4',6'-三羟基苯丙酮 2',4',6'-Trihydroxypropiophenone | 2295-58-1 | 1G | 110元 |
| 2025/05/22 | HY-100562 | 夫洛丙酮 Flopropione | 2295-58-1 | 100mg | 350元 |
常见问题列表
|
5-HT 1A Receptor
|
COMT
|
Flopropione在低于其T (g)温度下表现出无Lorentzian舒张。Flopropione在低于其T (g)温度下比Nifedipine具有更高的分子流动性。 Flopropione在整个温度范围表现出Arrhenius温度依赖性，推断高于T (g)时通过介电弛豫测量的tau（β）与低于T (g)时通过TAM/MDSC测量的tau（β）相一致。
The effect of Flopropione as an antispasmodic agent on the rate of passing a calculus from the urinary tract has been compared retrospectively with patients in whom passage was spontaneous. Flopropine has been shown, with statistical significance, to be superior to the control in cumulative passage rate after initiation of administration. Flopropine has been shown to exert a spasmolytic effect not only on smooth muscle of the gastrointestinal tract but also on smooth muscle of the pancreatobiliary and urinary systems.